The Company had approximately $21.8 million in cash and cash equivalents at September 30, 2008. Cash used in operations for the first nine months of 2008 was $13.0 million.
HIV Tropism Testing
"Monogram's enhanced Trofile Assay, introduced earlier this year with a thirty-fold improvement in sensitivity, has allowed a very important new analysis of Pfizer Inc.'s phase III trial of Selzentry(TM) (maraviroc) in treatment naive individuals with CCR5-tropic HIV-1, known as the 'MERIT' study," said William Young, Monogram chief executive officer. "Data reported this week by Pfizer demonstrated that in this study, increased efficacy was shown as a result of the enrichment of the patient population by use of the enhanced version of Monogram's Trofile(TM) Assay." Results of the reanalysis of the "MERIT" trial were reported this week at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington DC.
Pfizer's HIV medication Selzentry (maraviroc) is approved for use in treatment-experienced individuals with R5-tropic HIV-1. In July 2007 Pfizer reported data from the phase III trial of Selzentry in treatment naive individuals ("MERIT"), in which patients had been selected for treatment by Monogram's Trofile Assay. The reported differences in outcome for individuals treated with Selzentry did not meet a predefined study endpoint of non-inferiority to an established first line treatment regimen. To week 48, 65% of individuals receiving Selzentry had HIV-1 RNA <50 copies/mL, compared to 69% of those individuals in the control arm of the trial.
In June 2008 Monogram introduced an enhanced sensitivity version of the
Trofile Assay, with 30-fold greater sensitivity to detect low-level X4 HIV
|SOURCE Monogram Biosciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved